Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 14/20 | 0.62 |
| ▸ | FLT3 | P36888 | 14/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889000 | 0.88 | KDR (0.69) | KITFLT3SRCKDR | |
| SCHEMBL20580588 | 0.87 | KIT (0.60) | KITFLT3NTRK1SRCKDR | |
| SCHEMBL29539419 | 0.82 | KIT (0.57) | KITFLT3NTRK1SRCKDR | |
| SCHEMBL22917465 | 0.82 | KIT (0.57) | KITFLT3NTRK1SRCKDR | |
| SCHEMBL20632601 | 0.82 | KIT (0.54) | KITFLT3NTRK1SRCKDR | |
| SCHEMBL22917493 | 0.81 | KIT (0.80) | KITFLT3NTRK1SRCKDR | |
| SCHEMBL22917522 | 0.81 | KIT (0.54) | KITFLT3NTRK1SRCLIMK1 | |
| SCHEMBL29616151 | 0.81 | FLT3 (0.54) | KITFLT3NTRK1SRCKDR | |
| SCHEMBL24292329 | 0.79 | FLT3 (0.75) | KITFLT3NTRK1SRCKDR | |
| SCHEMBL22917647 | 0.79 | KIT (0.55) | KITFLT3NTRK1SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KIT 957/4885FLT3 63/4885NTRK1 507/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KIT 957/4885FLT3 63/4885NTRK1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.